Another meta-analysis was conducted in China to investigate the benefits and safety profile of SGLT-2 inhibitors vs. oGLDs in T2DM patients with established cardiovascular diseases [12]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.